Metabolic factors and hip fracture risk in a large Austrian cohort study

Dominic, Erlangga; Brozek, Wolfgang; Peter, Raphael Simon; Fromm, Ella; Ulmer, Hanno; Rapp, Kilian; Concin, Hans; Nagel, Gabriële

doi:10.1016/j.bonr.2020.100244

Cited by 21 publications

(13 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a prospective study involving 1032 men and 1701 women aged ≥ 50 years, elevated BP was associated with increased risk of any or hip fracture in women, with similar but less precise estimates in men [ 21 ]. In another study, mean arterial pressure or hypertension was not shown to predict incident hip fracture, but the study was based only on 176 events in men and 458 in women, and did not account for the use of antihypertensive treatment [ 54 ].…”

Section: Blood Pressure May Influence Bone Healthmentioning

confidence: 99%

Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions

et al. 2021

View full text Add to dashboard Cite

Blood pressure and bone metabolism appear to share commonalities in their physiologic regulation. Specific antihypertensive drug classes may also influence bone mineral density. However, current evidence from existing observational studies and randomised trials is insufficient to establish causal associations for blood pressure and use of blood pressure-lowering drugs with bone health outcomes, particularly with the risks of osteoporosis and fractures. The availability and access to relevant large-scale biomedical data sources as well as developments in study designs and analytical approaches provide opportunities to examine the nature of the association between blood pressure and bone health more reliably and in greater detail than has ever been possible. It is unlikely that a single source of data or study design can provide a definitive answer. However, with appropriate considerations of the strengths and limitations of the different data sources and analytical techniques, we should be able to advance our understanding of the role of raised blood pressure and its drug treatment on the risks of low bone mineral density and fractures. As elevated blood pressure is highly prevalent and blood pressure-lowering drugs are widely prescribed, even small effects of these exposures on bone health outcomes could be important at a population level. KeywordsAntihypertensive drugs • Blood pressure • Bone fracture • Bone mineral density • Osteoporosis * D. Canoy

show abstract

Section: Blood Pressure May Influence Bone Healthmentioning

confidence: 99%

Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As a limitation, we had no precise data to differentiate between traumatic versus osteoporotic fractures of our patients. To resolve the issue of traumatic fracture, we conducted separate analyses according to age (>50 and ≤50 years), assuming the low prevalence of osteoporotic fragility fractures above the age of 50 years; the approach was applied in another study [ 38 ]. Accordingly, we did not find effect modifications of age in the association between WrC and incidence of any fracture.…”

Section: Discussionmentioning

confidence: 99%

Association between Wrist Circumference and Risk of Any Fracture in Adults: Findings from 15 Years of Follow-Up in the Tehran Lipid and Glucose Study

Zadeh

Moazzeni

Asgari

et al. 2022

JCM

View full text Add to dashboard Cite

We evaluated whether wrist circumference (WrC), as a novel anthropometric measure, is associated with incidences of any fractures. The study population included 8288 adults (45.3% men) aged ≥30 years, who were followed for incidences of any fractures from 31 January 1999 to 16 March 2016. We used Cox proportional hazard models adjusted for well-known risk factors to evaluate the association of WrC, both as continuous and categorical variables (bottom tertile as reference), with incidences of any fractures and major osteoporotic fractures (MOF). Over 15 years of follow-ups, 348 fractures occurred (men = 162). For a 1 cm increase in WrC, hazard ratios (HRs) were 1.18 (95% CI: 1.03–1.35) for incident any fractures and 1.22 (1.01–1.49) for incident MOF. In addition to WrC, age, female sex, lower BMI, higher WC, current smoking, and usage of steroidal medications were significantly associated with the incidences of any fractures. Moreover, participants in the middle and top tertiles of WrC had a higher risk of incidence for any fractures [HR = 1.62 (1.19–2.20) and 1.70 (1.14–2.55), respectively, p-value for trend = 0.012]. We presented WrC as a strong and independent risk factor for incidences of any fractures that might be considered in the risk prediction of bone fracture in Iranian adults.

show abstract

“…However, in humans, it has been shown that individuals with prediabetes retain a preservation of both bone mineral density (17)(18)(19)(20) and bone material strength (24). Moreover, there have been inconsistent reports involving the increment of hip fracture in prediabetic population (19,(21)(22)(23). Therefore, the detrimental effects of prediabetes on the skeleton remain to be elucidated in prediabetic patients.…”

Section: Discussionmentioning

confidence: 99%

“…Chen and colleagues ( 19 ) and Park and colleagues ( 21 ) demonstrated an increased risk of hip fractures in a prediabetic population. In contrast, Dominic and colleagues ( 22 ), and Iki and colleagues ( 23 ), demonstrated that hip fractures did not increase in a population with prediabetes. In addition, Dowson-Hughes and colleagues ( 24 ) showed the preservation of bone material strength in individuals with prediabetes.…”

Section: Introductionmentioning

confidence: 90%

Receptors of Advanced Glycation End Product (RAGE) Suppression Associated With a Preserved Osteogenic Differentiation in Patients With Prediabetes

et al. 2022

View full text Add to dashboard Cite

Type 2 diabetes is widely documented for osteogenic differentiation defect and impaired bone quality, which is related to the skeletal accumulation of advanced glycation end products (AGEs). Prediabetes is a condition in which hyperglycemia is lower than the threshold for the diagnosis of diabetes. Prediabetic animal models consistently demonstrate impaired osteogenic differentiation and deteriorated bone microarchitecture. However, no evidence shows defects in osteoblast development and skeletal effects of AGEs in prediabetic individuals. Therefore, it remains to be elucidated whether impaired osteogenic differentiation ability and altered cellular response to AGEs occur in patients with prediabetes. This cross-sectional study included 28 patients with prediabetes as defined by impaired fasting glucose criteria, fasting plasma glucose (FPG) between 100–125 mg/dl and 17 age-matched normoglycemic controls to elucidate osteogenic differentiation and AGER expression in the PBMC derived from those individuals. The PBMC-isolated from both groups showed similar rates of expression of osteoblast-specific genes, namely, ALPL, BGLAP, COL1A1, and RUNX2/PPAR (89.3% and 88.2%, p = 1.000), and showed comparable levels of expression of those genes. By using age- and pentosidine-matched normoglycemic individuals as references, the PBMC-isolated from prediabetic patients demonstrated lower expression of both AGER and BAX/BCL2. The expression of AGER and BAX/BCL2 significantly correlated to each other (r = 0.986, p <0.0001). The multivariate analysis demonstrated that serum pentosidine is an independent risk factor for AGER expression. With logistic regression analysis, the area under the ROC curve (AUC) for serum pentosidine at the cut-off level of 2.1 ng/ml and FPG at 100 mg/dl, which is a cut-off point for prediabetes, was significantly higher for predicting AGER expression than that of serum pentosidine alone (0.803 vs 0.688, p = 0.048), indicating that serum pentosidine was a good predictor of AGER expression in prediabetic individuals. In conclusion, this study demonstrated a preserved osteogenic differentiation in the PBMC derived from prediabetic individuals. In addition, those PBMC with preserved osteogenic differentiation potential showed the suppression of both cellular RAGE and apoptotic-related signals. Serum pentosidine was an independent risk factor for cellular RAGE expression and is conceivably a good predictor for AGER suppression in prediabetic individuals.

show abstract

Metabolic factors and hip fracture risk in a large Austrian cohort study

Cited by 21 publications

References 55 publications

Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions

Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions

Association between Wrist Circumference and Risk of Any Fracture in Adults: Findings from 15 Years of Follow-Up in the Tehran Lipid and Glucose Study

Receptors of Advanced Glycation End Product (RAGE) Suppression Associated With a Preserved Osteogenic Differentiation in Patients With Prediabetes

Contact Info

Product

Resources

About